IASLC 2022 Targeted Therapies of Lung Cancer Meeting Transitions to Fully Virtual
Because of ongoing concerns caused by COVID-19 and the global surge in Omicron cases, the IASLC is transitioning the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC22) scheduled for February 22-26, in Santa Monica, California, to a fully virtual worldwide event. The TTLC22 virtual meeting will include both live-stream interaction and on-demand content.
Those who have already registered for the in-person event will be automatically registered for the Worldwide Virtual Event and will receive a refund for the difference in registration fees. Additional details, dates, and program information for TTLC22 and other 2022 meetings will be routinely updated at IASLC.org, the official source of updates to all IASLC meetings and events.
First Positive Study Results Reported for Pembrolizumab in Adjuvant Stage IB-IIIA NSCLC
The European Organization for Research and Treatment of Cancer (EORTC) and the European Thoracic Oncology Platform (ETOP) have reported that the Phase 3 KEYNOTE-091 trial investigating the PD-1 inhibitor pembrolizumab met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA NSCLC following surgical resection regardless of PD-L1 expression.
Based on an interim analysis conducted by an independent data monitoring committee, adjuvant treatment with pembrolizumab resulted in a statistically significant and clinically meaningful improvement in DFS compared with placebo in the all-comer population of patients with stage IB-IIIA NSCLC. Results will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.
GO2 Foundation for Lung Cancer Hires Joelle Fathi, DNP, as Chief Healthcare Delivery Officer
The GO2 Foundation for Lung Cancer recently announced the hiring of Joelle Fathi, DNP, an adult acute care nurse practitioner and nurse educator with more than 30 years of experience. She will serve as Chief Healthcare Delivery Officer.
Fathi has a long-standing relationship with GO2 Foundation as a presenter at the foundation’s annual Centers of Excellence Summit and as a member of the GO2 Foundation’s Scientific Leadership Board.
As Chief Healthcare Delivery Officer, Fathi will lead the GO2 Foundation’s Excellence in Screening and Care department, which includes the foundation’s Centers of Excellence, a network consisting of more than 850 primarily community-based medical facilities providing excellence in lung cancer early detection, diagnosis, treatment, and survivorship.
